Research programme: monoclonal antibodies against MERS - Regeneron/Sanofi

Drug Profile

Research programme: monoclonal antibodies against MERS - Regeneron/Sanofi

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Middle East respiratory syndrome coronavirus

Most Recent Events

  • 02 Oct 2017 Regeneron Pharmaceuticals plans a NIH-sponsored phase I trial for Middle East respiratory syndrome coronavirus by the end of 2017
  • 22 Aug 2016 Regeneron Pharmaceuticals enters into a collaboration agreement with Sanofi to develop human monoclonal antibodies for Middle East respiratory syndrome coronavirus before August 2016
  • 22 Aug 2016 Regeneron receives grant from Biomedical Advanced Research and Development Authority (BARDA) for antibody drug candidates development in Middle East respiratory syndrome coronavirus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top